Introduction: Urinary tract infections (UTI) are the most common bacterial infections affecting humans.. Fosfomycin has been approved for use in uncomplicated UTI caused by E. coli and Enterococcus. However, data regarding sensitivity of organisms causing hospital acquired or complicated UTI is scarce worldwide. We aimed to determine the in vitro sensitivity of drug resistant organisms causing hospital acquired and complicated UTI towards fosfomycin. Materials and Methods: Over a 6 month period, urine samples were processed as per standard microbiological protocols. Bacterial isolates were identified by routine microbiological methods followed by automated methods. Antibiotic sensitivity tests were done for different antibiotics. Fosfomycin sensitivity was tested by disc diffusion assay and minimum inhibitory concentration (MIC) was determined by E test method. Results: A total of 248` organisms causing hospital acquired and/or complicated UTI were isolated Conclusions: This study suggests that fosfomycin has the potential to replace the parenteral antibiotics for treating complicated or hospital acquired lower UTI especially in case of Enterobacteriaceae.
INTRODUCTION
Urinary tract infections (UTI) are the most common bacterial infections affecting humans [1] . They can be uncomplicated or complicated urinary tract infections (cUTIs), the latter occurring in patients with anatomic or functional abnormalities of the urinary tract or in those with significant comorbidities [2] . UTI can also be classified as community acquired or hospital acquired. Majority of UTIs can be attributed to Escherichia coli, Klebsiella pneumoniae and Staphylococcus saprophyticus in case of community acquired UTI while in case of hospital acquired UTI, more unusual microorganisms such as Staphylococcus aureus, Enterococcus spp, Proteus spp, Pseudomonas aeruginosa, Acinetobacter spp, and Candida spp [14] are implicated with a higher likelihood of antimicrobial resistance in addition, reflecting the attributes of the hospital flora. In case of cUTI, there is a higher risk of relapse, recurrence and mortality compared with uncomplicated UTIs [2] and more often than not, treatment guideline options have to be tailored to individual circumstances.
With increasing reports of ESBL, AmpC and carbapenemases producing bacteria causing UTI [3, 5] , the decision to start the correct antibiotic at the appropriate time is becoming a challenge for the practicing physician. Current recommendations of the Infectious Diseases Society of America (IDSA) as well as European Society for Clinical Microbiology and Infectious Diseases (ESCMID) recommends fosfomycin and as one of the firstline agents to treat acute uncomplicated UTIs in adult females [6] .
Fosfomycin is a phosphonic acid derivative, available as an oral formulation of fosfomycin tromethamine, a 5.7gram powder sachet [7] .
Approximately 40% of an oral dose of fosfomycin is excreted unchanged in urine following oral administration of a single dose. The mean urine fosfomycin concentration is 706 mg/L and declines to 10 mg/L in samples collected 72h after the dose [3] . It exerts its action by irreversible inhibition of MurA (UDPN acetylglucosamine3enolpyruvyl transferase), the cytosolic enzyme responsible for the first step in the peptidoglycan biosynthesis pathway that produces UDPNacetylmuramic acid [7] . This is a unique mechanism of action compared to other cell wall inhibitors suggesting that cross resistance between these drugs is unlikely. Fosfomycin enters the cytosol either by the glucose6phosphate (G6P) inducible hexose monophosphate transport (UhpT) system which is the primary portal, or less efficiently via the glycerol3phosphate) uptake (GlpT) system. Most Enterobacteriaceae, Enterococcus spp, and Staphylococcus spp. possess the UhpT transport system in their cell membrane [1] .
The efficiency of fosfomycin against E. coli and Enterococcus, organisms that commonly cause community acquired UTI is well established. However, the data regarding the sensitivity of complicated UTI or hospital acquired organisms towards fosfomycin is lacking not only from India but also worldwide. Hence, we attempted to study the organisms causing hospital acquired and complicated UTI in our hospital and establish their in vitro sensitivity towards fosfomycin as a first step towards the use of fosfomycin for in patient treatment of UTI. [12] . In case of fosfomycin, sensitivity was also compared with European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines [13] .
MATERIALS AND METHODS
Geometric MIC was calculated by Graph Pad Prism Software and oneway analysis of variance (ANOVA) with two sided Bonferroni multiple comparison test was performed for assessment of significance. Statistical significance was defined when p value was < 0.05.
RESULTS
A total of 24,328 urine samples with clinical suspicion of UTI were processed. Of these, 2,510(10.32%) showed significant growth of pathogens. Majority were gram negative bacilli 1,720(68.52%) and among them 248(14.41%) were drug resistant (including MDR, XDR and PDR) according to the definition and were thus included for further study. Of total 248, 134(54.03%) were from patients previously on antibiotics or with abnormalities of urinary tract or significant comorbidities and were thus deemed complicated UTI while remaining 114(45.97%) cases were acquired after 48 hours of hospitalization and were deemed hospital acquired UTI. Fig. 3 and Table 1 .
On comparison of resistance rates when interpretation was done according to CLSI and EUCAST, the number of isolates resistant to E. coli and K. pneumoniae did not change. However, as 6 isolates of P. aeruginosa had an MIC of 64 mg/L which is resistant according to EUCAST but sensitive according to CLSI, the resistance rate for P. aeruginosa rose to 24(37.5%) by EUCAST from 18(28.12%) by CLSI [ Table 2 ]. 
DISCUSSION
Fosfomycin represents a potentially reliable treatment option for UTIs, particularly the drug resistant variety [14] . However, significant discrepancies occur between broth and agar dilution methods for determining MIC of fosfomycin and so far, agar dilution is the only approved fosfomycin MIC susceptibility testing method [1] . As most automated systems for antimicrobial susceptibility testing are microdilutionbased methods, resistance to fosfomycin may be overestimated in laboratories employing such systems [15] . Hence, we attempted to study the in vitro susceptibility of drug resistant gram negative bacilli causing UTI by disc diffusion and E test method which are more commonly available and practiced in our country.
In this study, the most common drug resistant gram negative pathogens causing UTI were E. coli and K. pneumoniae followed by P. aeruginosa similar to many other studies [1619] . Overall 7.26% of the isolates were resistant to fosfomycin similar to other studies such as Seroy All drug resistant E. coli isolates in our study were sensitive to fosfomycin with 100% of the isolates having MIC of less than or equal to 16. This is similar to other studies [4, 15, 1720, 22, 23] . In our study, 97.4% of the K. pneumoniae isolates were sensitive to fosomycin. This is similar to the study by Falagas et al. [7] , Demir et al. [17] , PerdigaoNeto et al. [23] but in contrast to the study by Liu HY et al. [4] , Linsenmeyer et al. [16] , Livermore et al [24] and Chitra et al. [25] who found only 42%, 54%, 52%, and 64% of their K. pneumonaie isolates sensitive to fosfomycin respectively. Also, the mean MIC of K. pneumoniae was considerably more than that of E coli and this has been demonstrated in studies by other researchers as well [7, 21, 24, 26] .
In our study only 9(28.12%) of the 32 P. aeruginosa isolates were resistant to fosfomycin. Although this is clearly in excess of the resistance rates in Enterobacteriaceae, it is still much less than that reported by other researchers [17, 27, 28] . It is also in contrast to the study by Sultan et al. [18] and PerdigaoNeto et al. [23] in which 100% P aeruginosa isolates were sensitive to fosfomycin. The MICs of most P. aeruginosa isolates in our study was uncomfortably close the the breakpoint of 64ug/ml so empirical use of fosfomycin against P. aeruginosa would not be reasonable. Another interesting finding in our study was that although E test has been recently reported to perform poorly for P. aeruginosa [20, 23, 29] but in our study, there was absolute correlation between E test and disk diffusion.
As demonstrated by the geometric mean, there is a clear gradation of the MIC range with lowest values seen in E coli and significantly(p < 0.001) higher values seen in Klebsiella and Pseudomonas progressively and this has also been demonstrated by other studies [1, 23] . Thus the activity of fosfomycin may not be as reliable if used empirically in the absence of susceptibility testing for P. aeruginosa [20] . On the other hand, even with high MIC we cannot predict without clinical trials that therapeutic failure is the predictable outcome [30] .
The CLSI has established that for E. coli and Enterococcus, susceptibility to fosfomycin is defined as an MIC ≤64 mg/L but MIC breakpoints are lacking for other gramnegative organisms [12] . EUCAST defines a fosfomycin MIC ≤32 mg/L as susceptible for urinary Enterobacteriaceae and Pseudomonas isolates [13] . This discrepancy makes interpretation and comparison of results from different studies difficult [7] . However, in our study, the resistance rate of E. coli and K. pneumoniae did not vary between the two methods although the resistance rate of P. aeruginosa increased to 12(37.5%) when interpreted by EUCAST from 9(28.12%) when interpreted by CLSI guidelines. In case of E. coli and K. pneumoniae, other researchers have also reported minimal variation in resistance rates by the two methods [1, 22] while significant variation in the resistance rate of P. aeruginosa has also been reported [23] . However, an Indian study by Chitra C et al has reported significant variation even in the resistance rate of K. pneumoniae on interpretation by EUCAST(45%) and CLSI(13%) method [25] .
In our study, Colistin was the antimicrobial most sensitive against the isolates after fosfomycin and in case of P. aeruginosa, it was even slightly better than fosfomycin. However, Colistin is not a practical choice for UTI as nephrotoxicity is one of its prominent side effects and dose adjustment is required in case of renal impairment [31] . Similarly, other parenteral alternatives such as carbapenems, aminoglycosides and pipera cillin tazobactam performed poorly against these isolates.
Oral antibiotics which are advised as first line against UTI such as nitrofurantoin, cotrimoxazole and fluoroquinolones were also widely resistant and thus of no practical use for these isolates. This has been reported by many other researchers as well [2, 4, 16, 17, 19] This may be due to the widespread misuse of these drugs for every outpatient indication and lack of implementation of adequate guidelines for prescribing antibiotics. A notable exception is nitrofurantoin in the case of drug resistant E. Coli, 46(52.3%) of our 88 E. coli showed sensitivity indicating that this antibiotic still has some role in UTI caused by E. coli [16, 19] .
Looking at the pattern of sensitivity of these drug resistant isolates towards fosfomycin as compared to other commonly used antibiotics, it would not be unreasonable to suggest that fosfomycin has the potential to replace the parenteral antibiotics for treating complicated or hospital acquired lower UTI especially in case of Enterobacteriaceae. The benefits of such a shift would not only be the use of an oral antibiotic with an excellent safety profile achieving high concentration in the urine but also preventing the emergence of resistant microorganisms while reserving the parenteral antibiotics for a more aggressive systemic infection. However, such a decision will need the backing of clinical trials to ascertain its rationality.
CONCLUSION
The satisfaction of improved patient survival is often threatened by the development of health care associated infections, the most common of which is UTI often caused by a drug resistant bacteria. As we stare down the barrel of dwindling treatment options, with their own unacceptable toxicities, we are forced to look back at the antimicrobials we discarded and re think our management strategies. Our study suggests that fosfomycin is one such drug which is safe, with minimal adverse effects, achieves high concentration in urine, has low levels of non transmissible resistance among bacteria and thus can be used in cases of hospital acquired or complicated UTIs on the basis of a sound test for susceptibility.
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